Cytokinetics (CYTK) EBITDA (2016 - 2025)
Historic EBITDA for Cytokinetics (CYTK) over the last 16 years, with Q4 2024 value amounting to -$153.0 million.
- Cytokinetics' EBITDA fell 1248.02% to -$153.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$587.1 million, marking a year-over-year decrease of 1233.18%. This contributed to the annual value of -$587.1 million for FY2024, which is 1233.18% down from last year.
- Cytokinetics' EBITDA amounted to -$153.0 million in Q4 2024, which was down 1248.02% from -$154.1 million recorded in Q3 2024.
- Cytokinetics' 5-year EBITDA high stood at -$3.6 million for Q3 2020, and its period low was -$154.1 million during Q3 2024.
- Over the past 5 years, Cytokinetics' median EBITDA value was -$110.3 million (recorded in 2022), while the average stood at -$92.3 million.
- As far as peak fluctuations go, Cytokinetics' EBITDA soared by 8799.93% in 2020, and later crashed by 204206.53% in 2021.
- Cytokinetics' EBITDA (Quarter) stood at -$44.7 million in 2020, then rose by 29.87% to -$31.4 million in 2021, then tumbled by 331.6% to -$135.4 million in 2022, then decreased by 0.46% to -$136.0 million in 2023, then fell by 12.48% to -$153.0 million in 2024.
- Its EBITDA stands at -$153.0 million for Q4 2024, versus -$154.1 million for Q3 2024 and -$143.8 million for Q2 2024.